Compare TITN & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TITN | REPL |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 443.9M | 407.1M |
| IPO Year | 2007 | 2018 |
| Metric | TITN | REPL |
|---|---|---|
| Price | $18.35 | $11.45 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 9 |
| Target Price | ★ $19.00 | $5.67 |
| AVG Volume (30 Days) | 248.6K | ★ 3.8M |
| Earning Date | 05-21-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,427,107,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.21 | $1.50 |
| 52 Week High | $25.00 | $13.24 |
| Indicator | TITN | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 37.97 | 70.22 |
| Support Level | $15.32 | $6.81 |
| Resistance Level | $20.47 | N/A |
| Average True Range (ATR) | 0.98 | 0.92 |
| MACD | -0.18 | -0.05 |
| Stochastic Oscillator | 3.98 | 73.98 |
Titan Machinery Inc owns and operates a network of full-service agricultural and construction equipment stores. The company sells and repairs agricultural equipment, including machinery and attachments for large-scale farming and home and gardening purposes, as well as construction equipment. It operates through following segments: The Agriculture segment sells, services, and rents machinery and related parts and attachments, for uses ranging from large-scale farming to home and garden use, The construction segment sells, services, and rents machinery, and related parts and attachments, for uses ranging from heavy construction to light industrial machinery use, and the Europe and Australia segments.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.